Fkbp52-specific androgen receptor inhibitor, mjc13, for use in treating breast cancer
AssigneesBoard of Regents, The University of Texas System, The Regents of the University of Colorado, a body corporate
InventorsMarc B. Cox, Jennifer Richer
Life of this patent
Estimating the term…
Abstract
Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
Claims20
A method of treating androgen receptor positive breast cancer comprising administering to a subject having breast cancer a therapeutically effective amount of a compound having a chemical structure of Formula I
A method of treating androgen receptor positive breast cancer comprising administering to a subject having breast cancer a therapeutically effective amount of enzalutamide and a compound having a chemical structure of Formula I
Dependencies are inferred from the claim text.